These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38184414)

  • 1. Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer.
    Pederzoli F; Riba M; Venegoni C; Marandino L; Bandini M; Alchera E; Locatelli I; Raggi D; Giannatempo P; Provero P; Lazarevic D; Moschini M; Lucianò R; Gallina A; Briganti A; Montorsi F; Salonia A; Necchi A; Alfano M
    Eur Urol; 2024 May; 85(5):417-421. PubMed ID: 38184414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
    Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
    Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
    Necchi A; Basile G; Gibb EA; Raggi D; Calareso G; de Padua TC; Patanè D; Crupi E; Mercinelli C; Cigliola A; Tateo V; Giannatempo P; Moschini M; Briganti A; Montorsi F; Messina A; Ross JS; Pavlick D; De Cobelli F; Brembilla G
    BJU Int; 2024 Feb; 133(2):214-222. PubMed ID: 37803523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
    Necchi A; de Jong JJ; Raggi D; Briganti A; Marandino L; Gallina A; Bandini M; Dabbas B; Davicioni E; Capitanio U; Montorsi F; Seiler R; Wright JL; Lotan Y; Black PC; Gibb EA
    Eur Urol; 2021 Aug; 80(2):149-159. PubMed ID: 33785257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Urol Oncol; 2021 Apr; 39(4):235.e15-235.e21. PubMed ID: 33071107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
    Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
    J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
    Necchi A; Bandini M; Calareso G; Raggi D; Pederzoli F; Farè E; Colecchia M; Marandino L; Bianchi M; Gallina A; Colombo R; Fossati N; Gandaglia G; Capitanio U; Dehò F; Giannatempo P; Lucianò R; Salonia A; Madison R; Ali SM; Chung JH; Ross JS; Briganti A; Montorsi F; De Cobelli F; Messina A
    Eur Urol; 2020 May; 77(5):636-643. PubMed ID: 31882281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
    Briganti A; Gandaglia G; Scuderi S; Gallina A; Colombo R; Fossati N; Barletta F; Pellegrino A; Nocera L; Montorsi F; Necchi A
    Eur Urol; 2020 May; 77(5):576-580. PubMed ID: 31911010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.
    Necchi A; Raggi D; Giannatempo P; Marandino L; Farè E; Gallina A; Colecchia M; Lucianò R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Dittamore R; Liu Y; Davicioni E; Ross JS; de Jong JJ; Briganti A; Montorsi F; Gibb EA
    Eur Urol Oncol; 2021 Dec; 4(6):1001-1005. PubMed ID: 32417369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial.
    Basile G; Bandini M; Gibb EA; Ross JS; Raggi D; Marandino L; Costa de Padua T; Crupi E; Colombo R; Colecchia M; Lucianò R; Nocera L; Moschini M; Briganti A; Montorsi F; Necchi A
    Clin Cancer Res; 2022 Dec; 28(23):5107-5114. PubMed ID: 36190522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?
    Pederzoli F; Bandini M; Raggi D; Marandino L; Basile G; Alfano M; Colombo R; Salonia A; Briganti A; Gallina A; Montorsi F; Necchi A
    Eur Urol; 2021 Sep; 80(3):319-322. PubMed ID: 34053782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study
    Bandini M; Gibb EA; Gallina A; Raggi D; Marandino L; Bianchi M; Ross JS; Colecchia M; Gandaglia G; Fossati N; Pederzoli F; Lucianò R; Colombo R; Salonia A; Briganti A; Montorsi F; Necchi A
    Ann Oncol; 2020 Dec; 31(12):1755-1763. PubMed ID: 32979511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
    Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
    Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study.
    Trevisani F; Di Marco F; Raggi D; Bettiga A; Vago R; Larcher A; Cinque A; Salonia A; Briganti A; Capitanio U; Necchi A; Montorsi F
    Int J Cancer; 2021 Jul; 149(1):186-190. PubMed ID: 33720424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?
    Pederzoli F; Bandini M; Marandino L; Raggi D; Giannatempo P; Salonia A; Gallina A; Briganti A; Montorsi F; Necchi A
    Eur Urol Oncol; 2021 Dec; 4(6):1006-1010. PubMed ID: 32847746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.
    Cao C; Fu Z; Liu Y; Zhou A; Wang J; Shou J
    Front Immunol; 2021; 12():684879. PubMed ID: 34177933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.